Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Compare top high-yield ETFs by income potential and durability to select funds that optimize retirement cash flow and resilience.
27,330 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Ethereum sits in a tight range while on-chain tokenized Treasuries on the network surpass $8 billion, marking a major...
Amazon faces a pullback even as cloud, ads, and silicon efforts pick up speed. Analysts see roughly 36% upside over t...
A weekend of good meals and strong friendships can teach big lessons in budgeting and priorities. Explore how the Fiv...
In 2025, 50 donors gave a combined $22.4 billion to charity, up 35% from 2024 inflation-adjusted totals. Bill Gates r...
SoundHound posted revenue gains for the quarter, yet earnings slipped as acquisition-related costs weighed on results...
Ripple's XRP sinks about two-thirds from its peak, but the chatter around shocking ripple price predictions persists ...
A massive debt issuance reveals where Amazon is headed under Andy Jassy. This article breaks down the implications fo...
Uber expands its autonomous-vehicle ambitions by teaming up with Zoox, clouding the landscape with more AV partners a...
Is AMD stock still a good buy or is it too late to join the rally? This practical guide breaks down timing, value, an...
Stocks surged on unconfirmed chatter of an Apple chip deal with Intel, fueling bets on Intel’s foundry business. Anal...
A high-profile insider sale puts Credit Acceptance and its subprime finance niche in the spotlight. This piece breaks...